Review



recombinant human ccl22 (rhccl22; 69 a.a  (PeproTech)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    PeproTech recombinant human ccl22 (rhccl22; 69 a.a
    <t>rhCCL22-loaded</t> PLGA microparticles exhibit different size distribution based on the manufacturing method. ( a , b ) Volume-weighted size distributions and ( c , d ) representative scanning electron microscopy images of rhCCL22-loaded PLGA microparticles that were prepared by ( a , c ) microfluidics or ( b , d ) conventional methods.
    Recombinant Human Ccl22 (Rhccl22; 69 A.A, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant human ccl22 (rhccl22; 69 a.a/product/PeproTech
    Average 90 stars, based on 1 article reviews
    recombinant human ccl22 (rhccl22; 69 a.a - by Bioz Stars, 2026-03
    90/100 stars

    Images

    1) Product Images from "Investigation of the Impact of Manufacturing Methods on Protein-Based Long-Acting Injectable Formulations: A Comparative Assessment for Microfluidics vs. Conventional Methods"

    Article Title: Investigation of the Impact of Manufacturing Methods on Protein-Based Long-Acting Injectable Formulations: A Comparative Assessment for Microfluidics vs. Conventional Methods

    Journal: Pharmaceutics

    doi: 10.3390/pharmaceutics16101264

    rhCCL22-loaded PLGA microparticles exhibit different size distribution based on the manufacturing method. ( a , b ) Volume-weighted size distributions and ( c , d ) representative scanning electron microscopy images of rhCCL22-loaded PLGA microparticles that were prepared by ( a , c ) microfluidics or ( b , d ) conventional methods.
    Figure Legend Snippet: rhCCL22-loaded PLGA microparticles exhibit different size distribution based on the manufacturing method. ( a , b ) Volume-weighted size distributions and ( c , d ) representative scanning electron microscopy images of rhCCL22-loaded PLGA microparticles that were prepared by ( a , c ) microfluidics or ( b , d ) conventional methods.

    Techniques Used: Electron Microscopy

    Representative scanning electron microscopy images demonstrate the surface morphology and inner porosity differences for rhCCL22-loaded PLGA microparticles. PLGA microparticles were prepared by ( a , c ) microfluidics and ( b , d ) conventional methods. Arrows in ( d ) highlight some examples of the inner pore connections.
    Figure Legend Snippet: Representative scanning electron microscopy images demonstrate the surface morphology and inner porosity differences for rhCCL22-loaded PLGA microparticles. PLGA microparticles were prepared by ( a , c ) microfluidics and ( b , d ) conventional methods. Arrows in ( d ) highlight some examples of the inner pore connections.

    Techniques Used: Electron Microscopy

    rhCCL22 encapsulation (%) in the PLGA microparticles shows a significant difference depending on the manufacturing process: microfluidics vs. conventional methods. ** p ≤ 0.01.
    Figure Legend Snippet: rhCCL22 encapsulation (%) in the PLGA microparticles shows a significant difference depending on the manufacturing process: microfluidics vs. conventional methods. ** p ≤ 0.01.

    Techniques Used: Encapsulation

    rhCCL22 release kinetics from PLGA microparticles demonstrates different release kinetics according to the manufacturing method. ( a ) Microparticles prepared by the microfluidics method showed a zero-order delayed (~2 days) release profile. ( b ) Microparticles prepared by the conventional method presented a zero-order release profile.
    Figure Legend Snippet: rhCCL22 release kinetics from PLGA microparticles demonstrates different release kinetics according to the manufacturing method. ( a ) Microparticles prepared by the microfluidics method showed a zero-order delayed (~2 days) release profile. ( b ) Microparticles prepared by the conventional method presented a zero-order release profile.

    Techniques Used:

    Batch-to-batch variations in the size distribution of rhCCL22-loaded PLGA microparticles when PLGA microparticles were prepared by ( a ) microfluidics and ( b ) conventional methods.
    Figure Legend Snippet: Batch-to-batch variations in the size distribution of rhCCL22-loaded PLGA microparticles when PLGA microparticles were prepared by ( a ) microfluidics and ( b ) conventional methods.

    Techniques Used:

    Batch-to-batch variations in terms of rhCCL22 encapsulation (%) in PLGA microparticles regarding the manufacturing method. rhCCL22-loaded PLGA microparticles were prepared by ( a ) microfluidics and ( b ) conventional methods. * p ≤ 0.05, *** p ≤ 0.001, ns indicates non-significant difference.
    Figure Legend Snippet: Batch-to-batch variations in terms of rhCCL22 encapsulation (%) in PLGA microparticles regarding the manufacturing method. rhCCL22-loaded PLGA microparticles were prepared by ( a ) microfluidics and ( b ) conventional methods. * p ≤ 0.05, *** p ≤ 0.001, ns indicates non-significant difference.

    Techniques Used: Encapsulation

    Batch-to-batch variations in terms of rhCCL22 release kinetics from PLGA microparticles. rhCCL22-loaded PLGA microparticles were prepared by ( a ) microfluidics and ( b ) conventional methods.
    Figure Legend Snippet: Batch-to-batch variations in terms of rhCCL22 release kinetics from PLGA microparticles. rhCCL22-loaded PLGA microparticles were prepared by ( a ) microfluidics and ( b ) conventional methods.

    Techniques Used:



    Similar Products

    recombinant human ccl22 (rhccl22; 69 a.a  (PeproTech)
    90
    PeproTech recombinant human ccl22 (rhccl22; 69 a.a
    <t>rhCCL22-loaded</t> PLGA microparticles exhibit different size distribution based on the manufacturing method. ( a , b ) Volume-weighted size distributions and ( c , d ) representative scanning electron microscopy images of rhCCL22-loaded PLGA microparticles that were prepared by ( a , c ) microfluidics or ( b , d ) conventional methods.
    Recombinant Human Ccl22 (Rhccl22; 69 A.A, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant human ccl22 (rhccl22; 69 a.a/product/PeproTech
    Average 90 stars, based on 1 article reviews
    recombinant human ccl22 (rhccl22; 69 a.a - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    recombinant human ccl22 (rhccl22; 69 a.a)  (PeproTech)
    90
    PeproTech recombinant human ccl22 (rhccl22; 69 a.a)
    <t>rhCCL22-loaded</t> PLGA microparticles exhibit different size distribution based on the manufacturing method. ( a , b ) Volume-weighted size distributions and ( c , d ) representative scanning electron microscopy images of rhCCL22-loaded PLGA microparticles that were prepared by ( a , c ) microfluidics or ( b , d ) conventional methods.
    Recombinant Human Ccl22 (Rhccl22; 69 A.A), supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant human ccl22 (rhccl22; 69 a.a)/product/PeproTech
    Average 90 stars, based on 1 article reviews
    recombinant human ccl22 (rhccl22; 69 a.a) - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    rhCCL22-loaded PLGA microparticles exhibit different size distribution based on the manufacturing method. ( a , b ) Volume-weighted size distributions and ( c , d ) representative scanning electron microscopy images of rhCCL22-loaded PLGA microparticles that were prepared by ( a , c ) microfluidics or ( b , d ) conventional methods.

    Journal: Pharmaceutics

    Article Title: Investigation of the Impact of Manufacturing Methods on Protein-Based Long-Acting Injectable Formulations: A Comparative Assessment for Microfluidics vs. Conventional Methods

    doi: 10.3390/pharmaceutics16101264

    Figure Lengend Snippet: rhCCL22-loaded PLGA microparticles exhibit different size distribution based on the manufacturing method. ( a , b ) Volume-weighted size distributions and ( c , d ) representative scanning electron microscopy images of rhCCL22-loaded PLGA microparticles that were prepared by ( a , c ) microfluidics or ( b , d ) conventional methods.

    Article Snippet: Recombinant human CCL22 (rhCCL22; 69 a.a.) was purchased from PeproTech (Cranbury, NJ, USA).

    Techniques: Electron Microscopy

    Representative scanning electron microscopy images demonstrate the surface morphology and inner porosity differences for rhCCL22-loaded PLGA microparticles. PLGA microparticles were prepared by ( a , c ) microfluidics and ( b , d ) conventional methods. Arrows in ( d ) highlight some examples of the inner pore connections.

    Journal: Pharmaceutics

    Article Title: Investigation of the Impact of Manufacturing Methods on Protein-Based Long-Acting Injectable Formulations: A Comparative Assessment for Microfluidics vs. Conventional Methods

    doi: 10.3390/pharmaceutics16101264

    Figure Lengend Snippet: Representative scanning electron microscopy images demonstrate the surface morphology and inner porosity differences for rhCCL22-loaded PLGA microparticles. PLGA microparticles were prepared by ( a , c ) microfluidics and ( b , d ) conventional methods. Arrows in ( d ) highlight some examples of the inner pore connections.

    Article Snippet: Recombinant human CCL22 (rhCCL22; 69 a.a.) was purchased from PeproTech (Cranbury, NJ, USA).

    Techniques: Electron Microscopy

    rhCCL22 encapsulation (%) in the PLGA microparticles shows a significant difference depending on the manufacturing process: microfluidics vs. conventional methods. ** p ≤ 0.01.

    Journal: Pharmaceutics

    Article Title: Investigation of the Impact of Manufacturing Methods on Protein-Based Long-Acting Injectable Formulations: A Comparative Assessment for Microfluidics vs. Conventional Methods

    doi: 10.3390/pharmaceutics16101264

    Figure Lengend Snippet: rhCCL22 encapsulation (%) in the PLGA microparticles shows a significant difference depending on the manufacturing process: microfluidics vs. conventional methods. ** p ≤ 0.01.

    Article Snippet: Recombinant human CCL22 (rhCCL22; 69 a.a.) was purchased from PeproTech (Cranbury, NJ, USA).

    Techniques: Encapsulation

    rhCCL22 release kinetics from PLGA microparticles demonstrates different release kinetics according to the manufacturing method. ( a ) Microparticles prepared by the microfluidics method showed a zero-order delayed (~2 days) release profile. ( b ) Microparticles prepared by the conventional method presented a zero-order release profile.

    Journal: Pharmaceutics

    Article Title: Investigation of the Impact of Manufacturing Methods on Protein-Based Long-Acting Injectable Formulations: A Comparative Assessment for Microfluidics vs. Conventional Methods

    doi: 10.3390/pharmaceutics16101264

    Figure Lengend Snippet: rhCCL22 release kinetics from PLGA microparticles demonstrates different release kinetics according to the manufacturing method. ( a ) Microparticles prepared by the microfluidics method showed a zero-order delayed (~2 days) release profile. ( b ) Microparticles prepared by the conventional method presented a zero-order release profile.

    Article Snippet: Recombinant human CCL22 (rhCCL22; 69 a.a.) was purchased from PeproTech (Cranbury, NJ, USA).

    Techniques:

    Batch-to-batch variations in the size distribution of rhCCL22-loaded PLGA microparticles when PLGA microparticles were prepared by ( a ) microfluidics and ( b ) conventional methods.

    Journal: Pharmaceutics

    Article Title: Investigation of the Impact of Manufacturing Methods on Protein-Based Long-Acting Injectable Formulations: A Comparative Assessment for Microfluidics vs. Conventional Methods

    doi: 10.3390/pharmaceutics16101264

    Figure Lengend Snippet: Batch-to-batch variations in the size distribution of rhCCL22-loaded PLGA microparticles when PLGA microparticles were prepared by ( a ) microfluidics and ( b ) conventional methods.

    Article Snippet: Recombinant human CCL22 (rhCCL22; 69 a.a.) was purchased from PeproTech (Cranbury, NJ, USA).

    Techniques:

    Batch-to-batch variations in terms of rhCCL22 encapsulation (%) in PLGA microparticles regarding the manufacturing method. rhCCL22-loaded PLGA microparticles were prepared by ( a ) microfluidics and ( b ) conventional methods. * p ≤ 0.05, *** p ≤ 0.001, ns indicates non-significant difference.

    Journal: Pharmaceutics

    Article Title: Investigation of the Impact of Manufacturing Methods on Protein-Based Long-Acting Injectable Formulations: A Comparative Assessment for Microfluidics vs. Conventional Methods

    doi: 10.3390/pharmaceutics16101264

    Figure Lengend Snippet: Batch-to-batch variations in terms of rhCCL22 encapsulation (%) in PLGA microparticles regarding the manufacturing method. rhCCL22-loaded PLGA microparticles were prepared by ( a ) microfluidics and ( b ) conventional methods. * p ≤ 0.05, *** p ≤ 0.001, ns indicates non-significant difference.

    Article Snippet: Recombinant human CCL22 (rhCCL22; 69 a.a.) was purchased from PeproTech (Cranbury, NJ, USA).

    Techniques: Encapsulation

    Batch-to-batch variations in terms of rhCCL22 release kinetics from PLGA microparticles. rhCCL22-loaded PLGA microparticles were prepared by ( a ) microfluidics and ( b ) conventional methods.

    Journal: Pharmaceutics

    Article Title: Investigation of the Impact of Manufacturing Methods on Protein-Based Long-Acting Injectable Formulations: A Comparative Assessment for Microfluidics vs. Conventional Methods

    doi: 10.3390/pharmaceutics16101264

    Figure Lengend Snippet: Batch-to-batch variations in terms of rhCCL22 release kinetics from PLGA microparticles. rhCCL22-loaded PLGA microparticles were prepared by ( a ) microfluidics and ( b ) conventional methods.

    Article Snippet: Recombinant human CCL22 (rhCCL22; 69 a.a.) was purchased from PeproTech (Cranbury, NJ, USA).

    Techniques: